Traditional Chinese medicine for treating infantile asthma

Abstract

The invention relates to the field of traditional Chinese medicine formulas and particularly relates to a traditional Chinese medicine for treating infantile asthma. The traditional Chinese medicine is technically characterized by being prepared from the following raw materials in percent by weight: 5-11% of herbs of laminated sanicle, 8-10% of ophiopogon platyphyllum, 5-11% of dwarf mallow roots, 5-6% of mandragora, 8-14% of fimbristylis dichotoma, 5-11% of heterohairy monkshood roots, 6-11% of primula forbesii, 6-8% of piperic, 6-7% of affine cudweed, 6-8% of ligustrum lucidum roots, 5-6% of euphorbia kansui, 8-9% of inula flower, 8-9% of roughhaired holly roots and 6-8% of citron. The traditional Chinese medicine is prepared by the steps of soaking the fourteen crude drugs in water, decocting, and then, removing dregs to obtain filtrate. The traditional Chinese medicine is low in cost, free of obvious toxic or side effect, low in recurrence rate and capable of effectively treating infantile asthma.

Description

technical field [0001] The invention relates to a Chinese patent medicine preparation, in particular to a traditional Chinese medicine for treating asthma in children. Background technique [0002] As we all know, the incidence of cough variant asthma has gradually increased in recent years, and its pathogenesis has not been fully understood in western medicine research. Chronic inflammation, causing airway hyperresponsiveness, leading to reversible airway obstruction, is also related to the interaction of allergies, genetics, and neuroimmune factors. [0003] Due to the unclear pathogenesis, there is no specific treatment method and method in western medicine at present. Commonly used symptomatic treatment drugs include: glucocorticoids such as budesonide mixed solution for inhalation, bronchodilator β 2 Receptor agonists (salbutamol aerosol), theophylline drugs (aminophylline), anticholinergic drugs (atropine), leukotriene antagonists (montelukast sodium chewable tablets...

AI Technical Summary

Problems solved by technology

[0003] Due to the unclear pathogenesis, there is no specific treatment method and method in western medicine at present. Commonly used symptomatic treatment drugs include: glucocorticoids such as budesonide mixed solution for inhalation, bronchodilator β 2 Receptor agonists (salbutamol aerosol), theophylline drugs (aminophylline), anticholinergic drugs (atropine), leukotriene antagonists (montelukast sodium chewable tablets), antiallergic and stabilized drugs Cellular drugs (loratadine, sodium cromolyn, ketotifen), etc.

Single or combined medication is often used, there is no uniform medication standard, and the clinical curative effect is uncertain

Among them, albuterol aerosol and budesonide suspension for inhalation need oxygen-driven atomized inhalation, which is inconvenient to use, and some children have adverse reactions such as throat discomfort and moaning hoarseness; some children who take aminophylline and salbutamol tablets can Adverse reactions such as palpitations and tachycardia occur; Montelukast sodium chewable tablets are imported drugs, which are expensive and have uncertain curative effects; long-term use of antiallergic drugs may cause adverse reactions such as drowsiness, fatigue, nausea, dry mouth, and liver function damage , which greatly limits the clinical use of drugs, affects the recovery of the disease, and is prone to relapse after drug withdrawal, which brings serious physical and mental harm to children and parents.